Diabetes

Diabetes is a chronic condition that affects more than 380 million individuals worldwide.

According to the CDC, childhood obesity has more than doubled in children and quadrupled in adolescents in the past 30 years.

The number of Americans with diabetes rose from 5.6 million in 1980 to 21 million in 2014, with an additional 8.1 million individuals still undiagnosed.

Which OTC products should these pharmacists recommend?

Pharmacists are making a real difference in their communities and having a significant impact on the health care team.

As part of their Diabetes Awareness Month activities, supermarket partners Ralphs and Food 4 Less will conduct a check stand donation program to benefit the American Diabetes Association

Device identifies diabetes risk, in addition to diagnosing and monitoring patients.

Study examines the potential impact from GLP-1 agonists, or incretin mimetics to treat diabetes.

Roche has launched a new HbA1C test to identify diabetes risk and diagnose and monitor patients with diabetes.

Taking hypertension medications at bedtime can improve blood pressure control and reduce the risk of developing diabetes.

Guidelines include risk classification system to remind caregivers to examine diabetics' feet.

Around 11% of patients who use insulin have adverse drug reactions.

Lixisenatide is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist.

The FDA is considering approval for Sanofi's lixisenatide type 2 diabetes treatment.

Tresiba and Ryzodeg were originally denied approval due to adverse cardiovascular effects.

Eli Lilly and Company has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.

Discovery could lead to treatments that stop cancer recurrence.

The FDA today approved insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) to improve glucose control in adults with diabetes.

Merck has provided an update on its diabetes portfolio and re-affirmed the company's comprehensive, long-term commitment to patients with diabetes.

Type 2 diabetes drug canagliflozin (Invokana, Invokamet) can decrease bone strength and increase the risk of fractures, the FDA is warning health care professionals.

Use of diabetes therapy may increase the risk of bone fracture.

Jessica Kerr, PharmD, CDE, and assistant department chair at Southern Illinois University Edwardsville discusses what patients should know about Afrezza.

Tumors linked to high blood sugar can be successfully treated without affecting blood vessel growth.

Kristene Diggins, FAANP, CNE, NEA-BC, DNP, DCC, MBA, manager of professional practice at MinuteClinic, talks obstacles to managing diabetes, and how pharmacists overcome them.

Jessica Kerr, PharmD, CDE, and assistant department chair at Southern Illinois University Edwardsville discusses potential barriers to inhaled insulin, like Afrezza.